Speakers

 

 

 

Leila Abbas, Preclinical Lead, Rinri Therapeutics

Leila Abbas | Preclinical Lead | Rinri Therapeutics » speaking at Advanced Therapies

Elsa Abranches, Chief Scientific Officer, ViSync Technologies

Elsa Abranches | Chief Scientific Officer | ViSync Technologies » speaking at Advanced Therapies

Richard Adair, Virology Senior Manager, SGS

Richard Adair | Virology Senior Manager | SGS » speaking at Advanced Therapies

Luca Alberici, Senior Vice President and General Manager, AGC Biologics

Cynthia Alphonse, Sustainability Manager, time matters

Cynthia Alphonse | Sustainability Manager | time matters » speaking at Advanced Therapies

Nicola Ambler, Founder, The CGT Circle

Nicola Ambler | Founder | The CGT Circle » speaking at Advanced Therapies

Bahareh Amirloo, Lead Pharmacist for Advanced Therapy Medicinal Products, Manchester University NHS Foundation Trust

Bahareh Amirloo | Lead Pharmacist for Advanced Therapy Medicinal Products | Manchester University NHS Foundation Trust » speaking at Advanced Therapies

Borko Amulic, CSO/Associate Professor at University of Bristol, NeutroGen Therapeutics

Borko Amulic | CSO/Associate Professor at University of Bristol | NeutroGen Therapeutics » speaking at Advanced Therapies

Catia Andreassi, Director, AviadoBio

Catia Andreassi | Director | AviadoBio » speaking at Advanced Therapies

Claudia Andretta, Strategic Advisor, Sichem Bio

Claudia Andretta | Strategic Advisor | Sichem Bio » speaking at Advanced Therapies

Alvaro Avivar-Valderas, Associate Director - Cell Therapy Technology & Product Engine, Takeda

Alvaro Avivar-Valderas | Associate Director - Cell Therapy Technology & Product Engine | Takeda » speaking at Advanced Therapies

Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust

Owen Bain | Director | Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust » speaking at Advanced Therapies

Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics

Chris Baldwin | Vice President, Manufacturing & Supply | Resolution Therapeutics » speaking at Advanced Therapies

Robert Balfour, Investment Director, Alsa Ventures

Robert Balfour | Investment Director | Alsa Ventures » speaking at Advanced Therapies

Christopher Ballas, Chief Technology Officer, Castle Creek Biosciences

Ricardo Baptista, Chief Technology Officer, Smartcella

Tomasz Baran, Executive VP, PBKM/FamiCord Group

Samantha Barber, Chief Executive Officer, Gene People

Samantha Barber | Chief Executive Officer | Gene People » speaking at Advanced Therapies

Hollie Bartley, Group Leader, Process Development, Resolution Therapeutics

Hollie Bartley | Group Leader, Process Development | Resolution Therapeutics » speaking at Advanced Therapies

Cecile Bauche, Chief Scientific Officer, Alaya.bio

Cecile Bauche | Chief Scientific Officer | Alaya.bio » speaking at Advanced Therapies

Stefano Benvenuti, Head of Public Head of Public Affairs and Market Access, Fondazione Telethon

Stefano Benvenuti | Head of Public Head of Public Affairs and Market Access | Fondazione Telethon » speaking at Advanced Therapies

Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca

Katja Berg | Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU | AstraZeneca » speaking at Advanced Therapies

Benedikt Berninger, Professor of Developmental Neurobiology, King's College London

Jessica Birt, Chief Executive Officer, Concinnity Genetics

Jessica Birt | Chief Executive Officer | Concinnity Genetics » speaking at Advanced Therapies

Petter Bjorquist, CEO, VERIGRAFT AB

Jaap Jan Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center

Luca Bolondi, CEO and Co-Founder, Crane Biosciences Inc.

Luca Bolondi | CEO and Co-Founder | Crane Biosciences Inc. » speaking at Advanced Therapies

Angela Borghouts - de Ruijter, Senior Pricing and Market Access Manager, Cell Therapy, Gilead Sciences

Angela Borghouts - de Ruijter | Senior Pricing and Market Access Manager, Cell Therapy | Gilead Sciences » speaking at Advanced Therapies

Hugh JM Brady, Professor of Immunology, Imperial College London

Simon Briggs, Director, Advanced Analytics, Orchard Therapeutics

Simon Briggs | Director, Advanced Analytics | Orchard Therapeutics » speaking at Advanced Therapies

Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, The University of Sheffield

Henriette Burghoorn, Associate Director, Market Access, Gilead

Henriette Burghoorn | Associate Director, Market Access | Gilead » speaking at Advanced Therapies

Emmanuelle Cameau, Scientific Director Viral Vectors, Cytiva

Emmanuelle Cameau | Scientific Director Viral Vectors | Cytiva » speaking at Advanced Therapies

Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics

Lara Campana | SVP, Head of Research and Translational Science | Resolution Therapeutics » speaking at Advanced Therapies

Ambra Cappelletto, Principal Scientist, PureSpring Therapeutics

Ambra Cappelletto | Principal Scientist | PureSpring Therapeutics » speaking at Advanced Therapies

Paul Carter, Senior Director, MSAT, Quell Therapeutics

Paul Carter | Senior Director, MSAT | Quell Therapeutics » speaking at Advanced Therapies

Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca

Anna-Lina Cavallo | Director Discovery Cell and Gene Therapy integrated Bioanalysis | AstraZeneca » speaking at Advanced Therapies

Alessia Cavazza, Associate Professor in Gene Therapy, University College London

Alessia Cavazza | Associate Professor in Gene Therapy | University College London » speaking at Advanced Therapies

Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals

Fred Chereau | SVP, Strategy and Business Development | Alexion Pharmaceuticals » speaking at Advanced Therapies

Ella Churchill, Insights Manager Life Sciences, MedCity

Ella Churchill | Insights Manager Life Sciences | MedCity » speaking at Advanced Therapies

Giovanni Ciotta, Director - Cell Immunology, Astrazeneca

Giovanni Ciotta | Director - Cell Immunology | Astrazeneca » speaking at Advanced Therapies

Alison Clare, Senior Research Associate, University of Bristol

Alison Clare | Senior Research Associate | University of Bristol » speaking at Advanced Therapies

Angela Columbano, Head Business Development Partnership, Genethon

Angela Columbano | Head Business Development Partnership | Genethon » speaking at Advanced Therapies

Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics

Jean-Philippe Combal | Co-Founder And Chief Executive Officer | Vivet Therapeutics » speaking at Advanced Therapies

Oluwayemisi Corinaldi, Senior Director, Head of EU/International Regulatory Affairs, Spark Therapeutics

Oluwayemisi Corinaldi | Senior Director, Head of EU/International Regulatory Affairs | Spark Therapeutics » speaking at Advanced Therapies

Pedro Correa de Sampaio, CEO, Neobe therapeutics

Marta Costa, Principal Scientist, Stem and Immune Cells Bioengineering Lab, iBET

Marta Costa | Principal Scientist, Stem and Immune Cells Bioengineering Lab | iBET » speaking at Advanced Therapies

Matthieu Coutet, Partner, Sofinnova Partners

Vicki Coutinho, Consultant, Geni Consulting

Vicki Coutinho | Consultant | Geni Consulting » speaking at Advanced Therapies

Catriona Crombie, Head of Rare Disease Translational Challenge, LifeArc

Catriona Crombie | Head of Rare Disease Translational Challenge | LifeArc » speaking at Advanced Therapies

Elisa Cuevas, Director of Client Projects, 4basebio

Elisa Cuevas | Director of Client Projects | 4basebio » speaking at Advanced Therapies

Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society

Salmaan Dalvi | Chief Executive Officer | Global Regenerative Medicine Society » speaking at Advanced Therapies

Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy

Eric Michael David | Chief Executive Officer | BridgeBio Gene Therapy » speaking at Advanced Therapies

Lindsay Davies, CSO, NextCell Pharma

Niloofar Davoodi, Cell Therapy Product Operations Lead, Takeda

Niloofar Davoodi | Cell Therapy Product Operations Lead | Takeda » speaking at Advanced Therapies

Maike de la Roche, Senior Group Leader, The Cancer Research UK Cambridge Institute (CRUK-CI)

Marc de la Roche, Asst. Professor, University of Cambridge

Marc de la Roche | Asst. Professor | University of Cambridge » speaking at Advanced Therapies

Olga De La Rosa Morales, Madrid Cell Therapy Technology Head, Takeda

Olga De La Rosa Morales | Madrid Cell Therapy Technology Head | Takeda » speaking at Advanced Therapies

Johannes De Munter, Chief Executive Officer, Neuroplast

Carmen De Santo, Cruk New Investigator Fellow, Cancer Research UK

Carmen De Santo | Cruk New Investigator Fellow | Cancer Research UK » speaking at Advanced Therapies

Isaak Decoene, Postdoctoral researcher, KU Leuven

Isaak Decoene | Postdoctoral researcher | KU Leuven » speaking at Advanced Therapies

Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.

Colleen Delaney | Founder, Chief Scientific Officer | Deverra Therapeutics, Inc. » speaking at Advanced Therapies

Athanasios Didangelos, Director of Pharmacology,, Complement Therapeutics

Athanasios Didangelos | Director of Pharmacology, | Complement Therapeutics » speaking at Advanced Therapies

Evi Dimitriadou, Director, Taxo Bioscience

Evi Dimitriadou | Director | Taxo Bioscience » speaking at Advanced Therapies

Ben Doak, Head of Innovative Treatments, NHS England

Ben Doak | Head of Innovative Treatments | NHS England » speaking at Advanced Therapies

Anne Douar, COO, Vivet Therapeutics

Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Marcus Droege | Senior Advisor, Market Access & Commercial | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Advanced Therapies

Joseph Egan, Research Associate, Teeside University

Joseph Egan | Research Associate | Teeside University » speaking at Advanced Therapies

Victoria English, Co-Founder And Editor, Evernow Publications

Victoria English | Co-Founder And Editor | Evernow Publications » speaking at Advanced Therapies

Rui Estrela, Manager, SmartFreez, Lda

Mark Farmery, Chief Development Officer, Anocca Ab

Mark Farmery | Chief Development Officer | Anocca Ab » speaking at Advanced Therapies

Tim Farries, Independent Consultant Cell & Gene Therapies, Independent

Radmila Feldmann, Global manager Cell & Gene Therapies, time matters

Gregory Fiore, Former CEO, Exacis Biotherapeutics

Gregory Fiore | Former CEO | Exacis Biotherapeutics » speaking at Advanced Therapies

Jonathan Fisher, Group Leader, University College London

Jonathan Fisher | Group Leader | University College London » speaking at Advanced Therapies

Nerea Castillo Flores, Hematologist, Blood & Tissue Bank Center of Barcelona

Nerea Castillo Flores | Hematologist | Blood & Tissue Bank Center of Barcelona » speaking at Advanced Therapies

Mark Flower, Vice President - Business Development, Cryopreservation, Cryoport Systems

Lydia Foeken, Chief Executive Officer, WMDA

Veronica Foisor, Field Application Scientist, Unchained Labs

Veronica Foisor | Field Application Scientist | Unchained Labs » speaking at Advanced Therapies

David Foldes, Senior Clinical Research Fellow, Imperial College London

David Foldes | Senior Clinical Research Fellow | Imperial College London » speaking at Advanced Therapies

Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association

Miguel Forte, CEO, Kiji Tx

Miguel Forte | CEO | Kiji Tx » speaking at Advanced Therapies

Daniel Fowler, Research Fellow, UCL

Daniel Fowler | Research Fellow | UCL » speaking at Advanced Therapies

Nick France, Vice President, Head: Genomic Medicine Development Unit, Alexion, AstraZeneca Rare Disease

George Frodsham, Founder & CEO, MediSieve Limited

George Frodsham | Founder & CEO | MediSieve Limited » speaking at Advanced Therapies

Ibon Garitaonandia, Chief Scientific Officer, cellProthera

Terri Gaskell, CTO, Rinri Therapeutics

Terri Gaskell | CTO | Rinri Therapeutics » speaking at Advanced Therapies

Lina Gaydarova, Investment Manager, Novaterra

Lina Gaydarova | Investment Manager | Novaterra » speaking at Advanced Therapies

Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy

Josie Godfrey | Co-Founder and Chief Executive Officer | Realise Advocacy » speaking at Advanced Therapies

Ian Goodwin, Director, Program Design and CMC Strategy, Fujifilm

Ian Goodwin | Director, Program Design and CMC Strategy | Fujifilm » speaking at Advanced Therapies

Rabia Gowa, Pharmacy Lead for Innovative Treatments, NHS England

Rabia Gowa | Pharmacy Lead for Innovative Treatments | NHS England » speaking at Advanced Therapies

Andreja Gramc Livk, Head of Process Analytics, BIA Separations, a Sartorius Company

Roberto Gramignoli, Associate Professor, Karolinska Institutet

Roberto Gramignoli | Associate Professor | Karolinska Institutet » speaking at Advanced Therapies

Klaus Graumann, CEO, Phoenestra GmbH

Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperial College London

Uta Griesenbach | Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy; | Imperial College London » speaking at Advanced Therapies

Sonam Gurung, Postdoctoral Research Fellow, University College London

Sonam Gurung | Postdoctoral Research Fellow | University College London » speaking at Advanced Therapies

NAGY HABIB, Professor of Surgery, Imperial College London

Ben Hajir, Senior Business Development Manager, Abselion

Ben Hajir | Senior Business Development Manager | Abselion » speaking at Advanced Therapies

Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA

Eric Halioua | President & Chief Executive Officer | PDC*line pharma SA » speaking at Advanced Therapies

William Hall, Senior Process Technical expert, Autolus

William Hall | Senior Process Technical expert | Autolus » speaking at Advanced Therapies

Tom Hargroves, Consultant, Belmont Bio Consulting

Tom Hargroves | Consultant | Belmont Bio Consulting » speaking at Advanced Therapies

Matthias Hebben, CTO, Complement Therapeutics

Matthias Hebben | CTO | Complement Therapeutics » speaking at Advanced Therapies

Stijn Heessen, Chief Operating Officer, Alder Therapeutics

Laura Herbst, Group Manager, Fraunhofer-Institute for Production Technology

Laura Herbst | Group Manager | Fraunhofer-Institute for Production Technology » speaking at Advanced Therapies

Victor Hernandez, CSO, Axovia Therapeutics

Victor Hernandez | CSO | Axovia Therapeutics » speaking at Advanced Therapies

Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan

David Hipkiss, Executive Chair, AlveoGene

David Hipkiss | Executive Chair | AlveoGene » speaking at Advanced Therapies

Tom Hoggan, Founder, Hoggan Biotech Consulting

Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant

Lilian Hook | Director of Cell, Aphaeresis and Gene Therapies | NHS Blood and Transplant » speaking at Advanced Therapies

Volker Huppert, Chief Operating Officer, Glycostem Therapeutics BV

Volker Huppert | Chief Operating Officer | Glycostem Therapeutics BV » speaking at Advanced Therapies

Mr Adam Inche, CEO, Lentitek

Claire Irvine, Of Counsel, Beck Greener LLP

Claire Irvine | Of Counsel | Beck Greener LLP » speaking at Advanced Therapies

Reagan Jarvis, Chief Executive Officer, Anocca Ab

Reagan Jarvis | Chief Executive Officer | Anocca Ab » speaking at Advanced Therapies

James Jones, Honorary Consultant in Medical Oncology, University of Cambridge

Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences

Ron Jortner | Founder & Chief Executive Officer | Aspire Biosciences » speaking at Advanced Therapies

Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma

Angela Justice, Chief People Officer / Executive Advisor, Justice Group Advisors

Rahul Khetan, Venture Associate, UCB Ventures

Sven Kili, Partner, Saisei Ventures

Sven Kili | Partner | Saisei Ventures » speaking at Advanced Therapies

Lorenz Knackstedt, Chief Technology Officer & Co-Founder, NeutroGen Therapeutics

Lorenz Knackstedt | Chief Technology Officer & Co-Founder | NeutroGen Therapeutics » speaking at Advanced Therapies

Laura Koivusalo, Chief Executive Officer & Founder, StemSight

Laura Koivusalo | Chief Executive Officer & Founder | StemSight » speaking at Advanced Therapies

Anna Koptina, Head Of Regulatory Affairs, Mendus

Anna Koptina | Head Of Regulatory Affairs | Mendus » speaking at Advanced Therapies

Bence Kozma, Research Assistant PostDoc, TU Wien

Bence Kozma | Research Assistant PostDoc | TU Wien » speaking at Advanced Therapies

Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd

David Kuntin, Chief Executive Officer, Mesenbio

David Kuntin | Chief Executive Officer | Mesenbio » speaking at Advanced Therapies

Joanne Kurtzberg, Director, Marcus Center For Cellular Cures,, Duke University Medical Center

Joanne Kurtzberg | Director, Marcus Center For Cellular Cures, | Duke University Medical Center » speaking at Advanced Therapies

Lukasz Kwiatkowski, Product Development Supervisor, TC Biopharm

Lukasz Kwiatkowski | Product Development Supervisor | TC Biopharm » speaking at Advanced Therapies

Michael Kyriakides, Investment partner, Syncona Ltd

Michael Kyriakides | Investment partner | Syncona Ltd » speaking at Advanced Therapies

Holger Laux, Director of Viral Vector Process Development, CSL Behring

Holger Laux | Director of Viral Vector Process Development | CSL Behring » speaking at Advanced Therapies

Inês Leal Reis, Co-founder, Regenera

Inês Leal Reis | Co-founder | Regenera » speaking at Advanced Therapies

Juliette Lee, VP, EQT Life Sciences

Juliette Lee | VP | EQT Life Sciences » speaking at Advanced Therapies

Michelle Levene, Managing Director, 161 Consulting Ltd

Michelle Levene | Managing Director | 161 Consulting Ltd » speaking at Advanced Therapies

James Levine, President, Fondation Ipsen

James Levine | President | Fondation Ipsen » speaking at Advanced Therapies

Daniel Lewi, Co-founder & Chief Executive Officer, The Cure & Action for Tay-Sachs (CATS) Foundation

Daniel Lewi | Co-founder & Chief Executive Officer | The Cure & Action for Tay-Sachs (CATS) Foundation » speaking at Advanced Therapies

John Lewis, Project Manager, Advanced Therapies Wales and Midlands-Wales Advanced Therapy Treatment Centre

Robert Leydon, Group Leader, AAV, Oxgene A Wuxi Advanced Therapies Company

Robert Leydon | Group Leader, AAV | Oxgene A Wuxi Advanced Therapies Company » speaking at Advanced Therapies

Charles Li, Chief Business Officer, AAVnerGene

Charles Li | Chief Business Officer | AAVnerGene » speaking at Advanced Therapies

Laura Lombardi, Director of Pharmacology and Gene Therapy Research, Tenaya Therapeutics

Laura Lombardi | Director of Pharmacology and Gene Therapy Research | Tenaya Therapeutics » speaking at Advanced Therapies

Eleuterio Lombardo, Director of Cell Therapy Characterization & Development, Cell Therapies, Takeda

Eleuterio Lombardo | Director of Cell Therapy Characterization & Development, Cell Therapies | Takeda » speaking at Advanced Therapies

Jacek Lubelski, CTO, R&D Operations and Product Development, NanoCell Therapeutics

Jacek Lubelski | CTO, R&D Operations and Product Development | NanoCell Therapeutics » speaking at Advanced Therapies

Dominika Lukas, Associate Director of Allogeneic Immunotherapy, R&D, Miltenyi Biotec

Dominika Lukas | Associate Director of Allogeneic Immunotherapy, R&D | Miltenyi Biotec » speaking at Advanced Therapies

Shirley M Bartido, Director, Global Regulatory Affairs Oncology Cell Therapy, Takeda

John Maher, CSO, Leucid Bio

John Maher | CSO | Leucid Bio » speaking at Advanced Therapies

Salmah Mahmood Ahmed, Director of Quality and Regulation, Anthony Nolan

Salmah Mahmood Ahmed | Director of Quality and Regulation | Anthony Nolan » speaking at Advanced Therapies

Heather Main, Project Manager,, ATMP Sweden

Qasim Majid, Postdoctoral Research Scientist, University of Helsinki

Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London

Karl Johan Malmberg, Director, Precision Immunotherapy Alliance, Professor, The University of Oslo

Karl Johan Malmberg | Director, Precision Immunotherapy Alliance, Professor | The University of Oslo » speaking at Advanced Therapies

Anders Månsson, Chief Executive Officer, PHI

James March, Postdoctoral Research Assistant, Royal Holloway, University of London

James March | Postdoctoral Research Assistant | Royal Holloway, University of London » speaking at Advanced Therapies

Julius Mathews, Project Manager & Research Fellow, Fraunhofer Institute for Production Technology IPT

Marc-Olivier Mignon, Chief Executive Officer, CELLforCURE by SEQENS

Marc-Olivier Mignon | Chief Executive Officer | CELLforCURE by SEQENS » speaking at Advanced Therapies

Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills, LifeArc

Anji Miller | Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills | LifeArc » speaking at Advanced Therapies

Manal Mohammed, Senior Lecturer, University of Westminster

Manal Mohammed | Senior Lecturer | University of Westminster » speaking at Advanced Therapies

Deana Mohr, Chief Executive Officer, MUVON Therapeutics

Deana Mohr | Chief Executive Officer | MUVON Therapeutics » speaking at Advanced Therapies

Dame Molly Morag Stevens, John Black Professor of Bionanoscience, University of Oxford

Dame Molly Morag Stevens | John Black Professor of Bionanoscience | University of Oxford » speaking at Advanced Therapies

Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine

David Morrow, Senior scientific manager, EATRIS

David Morrow | Senior scientific manager | EATRIS » speaking at Advanced Therapies

Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies

Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics

Noor Mujahid | Head of Vector Process Development | NHS Centre for Cell Gene and Tissue Therapeutics » speaking at Advanced Therapies

Matthias Müllner, CEO, bespark*bio

Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center

Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz | Secretary General | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Advanced Therapies

Darren Nesbeth, Programme Director, University College London

Darren Nesbeth | Programme Director | University College London » speaking at Advanced Therapies

Katy Newton, Former Senior Vice President of Immunology and Process Development, Achilles Therapeutics Limited

Katy Newton | Former Senior Vice President of Immunology and Process Development | Achilles Therapeutics Limited » speaking at Advanced Therapies

Roberto Nitsch, Director, AstraZeneca

Theres Oakes, Former Head of Translational Science Product Characterisation, Achilles Therapeutics Limited

Theres Oakes | Former Head of Translational Science Product Characterisation | Achilles Therapeutics Limited » speaking at Advanced Therapies

Kieran O'Donnell, Director, Kieran O'Donnell Ltd

Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.

Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Brian O'Mahony, Chief Executive Officer, Irish Haemophilia Society

Brian O'Mahony | Chief Executive Officer | Irish Haemophilia Society » speaking at Advanced Therapies

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)

Nneka Onwudiwe | Former PRO/PE Regulatory Review Officer | Food and Drug Administration (FDA) » speaking at Advanced Therapies

Dominic O'Regan, Business Development Consultant & Investor, New Mosaic

Dominic O'Regan | Business Development Consultant & Investor | New Mosaic » speaking at Advanced Therapies

Maitane Ortiz Virumbrales, Associate Director, Cell Therapies, Takeda

Maitane Ortiz Virumbrales | Associate Director, Cell Therapies | Takeda » speaking at Advanced Therapies

George Pamenter, PhD Researcher, UCL

Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics

Francis Pang | Senior Vice President, Global Market Access and Geographic Expansion | Orchard Therapeutics » speaking at Advanced Therapies

Sarita Panula, Head of R&D and CMC, StemSight

Sarita Panula | Head of R&D and CMC | StemSight » speaking at Advanced Therapies

Anna-Pia Papageorgiou, Policy Officer, European Commission

Anna-Pia Papageorgiou | Policy Officer | European Commission » speaking at Advanced Therapies

Kerstin Papenfuss, Director Pharma, Deep Science Ventures

Kerstin Papenfuss | Director Pharma | Deep Science Ventures » speaking at Advanced Therapies

Trish Parry, Finder and Managing Director, INDICRO Ltd

Trish Parry | Finder and Managing Director | INDICRO Ltd » speaking at Advanced Therapies

Tanya Patel, Manager CTSM GCP Operations, BioNTech

Tanya Patel | Manager CTSM GCP Operations | BioNTech » speaking at Advanced Therapies

Shree Patel, Biotech and Life Sciences Consultant, Suriacon Consulting

Shree Patel | Biotech and Life Sciences Consultant | Suriacon Consulting » speaking at Advanced Therapies

Kinnari Patel, President, Head of R&D and COO, Rocket Pharma

Kinnari Patel | President, Head of R&D and COO | Rocket Pharma » speaking at Advanced Therapies

Dilip Patel, SVP, Pricing, Value & Access Strategy, Autolus

Dilip Patel | SVP, Pricing, Value & Access Strategy | Autolus » speaking at Advanced Therapies

Ashish Patel, Clinical Senior Lecturer in Vascular Surgery, King’s College London & Guy’s and St Thomas’ Hospital NHS Foundation Trust

Ashish Patel | Clinical Senior Lecturer in Vascular Surgery | King’s College London & Guy’s and St Thomas’ Hospital NHS Foundation Trust » speaking at Advanced Therapies

Tom Payne, Chief Operating Officer, Laverock Therapeutics

Tom Payne | Chief Operating Officer | Laverock Therapeutics » speaking at Advanced Therapies

Valentina Pennucci, Principal Scientist, Global Analytics, Orchard Therapeutics

Valentina Pennucci | Principal Scientist, Global Analytics | Orchard Therapeutics » speaking at Advanced Therapies

David Peritt, Chief Scientific Officer, Lupagen

David Peritt | Chief Scientific Officer | Lupagen » speaking at Advanced Therapies

Brian Philip, Primary Scientist, NIBRT

Brian Philip | Primary Scientist | NIBRT » speaking at Advanced Therapies

Rupa Pike, Global Head of Strategic Alliances, Catalent

Rupa Pike | Global Head of Strategic Alliances | Catalent » speaking at Advanced Therapies

Riccardo Privolizzi, Senior Research Fellow, University College London

Riccardo Privolizzi | Senior Research Fellow | University College London » speaking at Advanced Therapies

Nivetha R, CMC Specialist, Leucid Bio

Nivetha R | CMC Specialist | Leucid Bio » speaking at Advanced Therapies

Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc

Shahrooz Rabizadeh | CEO & Co-Founder | Sagittarius Bio, Inc » speaking at Advanced Therapies

Linda Randall, Associate Vice President, Biologics Development, Manufacturing & Control, Pharmaron

Linda Randall | Associate Vice President, Biologics Development, Manufacturing & Control | Pharmaron » speaking at Advanced Therapies

Lior Raviv, CTO, Pluri

Lior Raviv | CTO | Pluri » speaking at Advanced Therapies

Nicola Redfern, Director, NJ Redfern Ltd.

Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda

Pilar Redondo | Site Head Madrid, Cell Therapy Technology Center | Takeda » speaking at Advanced Therapies

Ajan Reginald, CEO, Roquefort Therapeutics PLC

Jack Reid, Co-founder, Unicorn Bio

Jack Reid | Co-founder | Unicorn Bio » speaking at Advanced Therapies

Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners

Giovanni Rizzo | Partner Biotech Fund | Indaco Venture Partners » speaking at Advanced Therapies

Michael Roberts, CEO, Chromatin Bioscience

Michael Roberts | CEO | Chromatin Bioscience » speaking at Advanced Therapies

Jessica Robinson, PD, Terrapinn

Jessica Robinson | PD | Terrapinn » speaking at Advanced Therapies

Miguel Rodrigues, Co-Founder, Smartfreez

Miguel Rodrigues | Co-Founder | Smartfreez » speaking at Advanced Therapies

Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET

Antonio Roldao | Head of Cell-based Vaccines Development Lab | IBET » speaking at Advanced Therapies

Alex Ross, Chair of Cord Blood Operations Committee, WMDA

Alex Ross | Chair of Cord Blood Operations Committee | WMDA » speaking at Advanced Therapies

Jeroen Rovers, Chief Medical Officer, Mendus

Sean Russell, Head of Regulatory Affairs, Telethon Foundation

Sean Russell | Head of Regulatory Affairs | Telethon Foundation » speaking at Advanced Therapies

Tara Sadeghi, Chief Operating Officer, Cellenkos

Tara Sadeghi | Chief Operating Officer | Cellenkos » speaking at Advanced Therapies

Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis

Chaminda Salgado, CMC Innovation Lead, CEPI

Chaminda Salgado | CMC Innovation Lead | CEPI » speaking at Advanced Therapies

Mark Sawicki, President & CEO, Cryoport Systems

Jordan Schecter, Vice President | Multiple Myeloma DAS Leader, Johnson and Johnson

Jordan Schecter | Vice President   | Multiple Myeloma DAS Leader | Johnson and Johnson » speaking at Advanced Therapies

Christian Schutt, Senior Scientist, CSL Behring Innovation GmbH

Christian Schutt | Senior Scientist | CSL Behring Innovation GmbH » speaking at Advanced Therapies

Fatma Senkesen, Executive Director, Head Divisional Projects, Lonza

Fatma Senkesen | Executive Director, Head Divisional Projects | Lonza » speaking at Advanced Therapies

Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca

Marta Serafini | Associate Professor, School of Medicine and Surgery | University of Milano-Bicocca » speaking at Advanced Therapies

Will Sherlock, Senior Scientist, Rinri Therapeutics

Will Sherlock | Senior Scientist | Rinri Therapeutics » speaking at Advanced Therapies

Anthony Shillings, Head of Vector Production, NHS Centre for Cell Gene and Tissue Therapeutics

Anthony Shillings | Head of Vector Production | NHS Centre for Cell Gene and Tissue Therapeutics » speaking at Advanced Therapies

Simon Sioen, Field Application Scientist, TrinceBio

Simon Sioen | Field Application Scientist | TrinceBio » speaking at Advanced Therapies

Chrysanthi Sitmalidou, Scientist II, Orchard Therapeutics

Chrysanthi Sitmalidou | Scientist II | Orchard Therapeutics » speaking at Advanced Therapies

Julia Skokowa, Head, Translational Oncology, Dept. Hematology and Oncology. Director Gene and RNA Therapy Center, University Hospital Tübingen

Julia Skokowa | Head, Translational Oncology, Dept. Hematology and Oncology. Director Gene and RNA Therapy Center | University Hospital Tübingen » speaking at Advanced Therapies

Owen Smith, Partner, 4BIO Capital

Owen Smith | Partner | 4BIO Capital » speaking at Advanced Therapies

Jorge Soza Ried, Head of Therapeutic Virus Development Laboratory, Boehringer Ingelheim Pharma GmbH&Co.KG

Jorge Soza Ried | Head of Therapeutic Virus Development Laboratory | Boehringer Ingelheim Pharma GmbH&Co.KG » speaking at Advanced Therapies

Oliver Spadiut, Univ. Professor & Head of the Research Area Biochemical Engineering, TU Wien

Oliver Spadiut | Univ. Professor & Head of the Research Area Biochemical Engineering | TU Wien » speaking at Advanced Therapies

Mike Spencer, Vice President of Oncology Market Access, Johnson & Johnson

Mike Spencer | Vice President of Oncology Market Access | Johnson & Johnson » speaking at Advanced Therapies

Mark Stockdale, Senior Director, Strategic Alliances, Asimov

Mark Stockdale | Senior Director, Strategic Alliances | Asimov » speaking at Advanced Therapies

Matthias Stöcker, Regulatory Capability Lead, Boehringer Ingelheim International GmbH

Matthias Stöcker | Regulatory Capability Lead | Boehringer Ingelheim International GmbH » speaking at Advanced Therapies

Weiheng Su, Head of AAV, Oxgene A Wuxi Advanced Therapies Company

Stephen Sullivan, COO, iPSirius

Stephen Sullivan | COO | iPSirius » speaking at Advanced Therapies

Mathias Svahn, Chief Executive Officer, NextCell Pharma

Mathias Svahn | Chief Executive Officer | NextCell Pharma » speaking at Advanced Therapies

Nathan Sweeney, ATMP Technical Strategy Director, Rentschler Biopharma

Nathan Sweeney | ATMP Technical Strategy Director | Rentschler Biopharma » speaking at Advanced Therapies

Hiroki Takai, Director, Investment Group, UK Office, Global Brain

Hiroki Takai | Director, Investment Group, UK Office | Global Brain » speaking at Advanced Therapies

Marina Tarunina, Research Director, Plasticell

Benjamin Taylor, Senior Director, Cell Immunology, AstraZeneca

Anike Te, Chief Strategy Officer, Lucideon

Dr. Panteli Theocharous, Chief Therapeutics Officer, Garuda Therapeutics, Inc.

Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics

Stefanos Theoharis | Chief Executive Officer | OneChain Immunotherapeutics » speaking at Advanced Therapies

Kayleigh Thirlwell, Director - Translational In Vitro Pharmacology, Resolution Therapeutics

Kayleigh Thirlwell | Director - Translational In Vitro Pharmacology | Resolution Therapeutics » speaking at Advanced Therapies

Steven Thompson, Vice President, Sales - Cell Processing, BioLife Solutions

Steven Thompson | Vice President, Sales - Cell Processing | BioLife Solutions » speaking at Advanced Therapies

Pamela Tranter, Head, Translational Research Group, Translational Research Office, University College London

Pamela Tranter | Head, Translational Research Group, Translational Research Office | University College London » speaking at Advanced Therapies

Marco Traub, Chief Executive Officer, Tesct—Society

Tim Traynor, Technical Sales Specialist, Aldevron

Tim Traynor | Technical Sales Specialist | Aldevron » speaking at Advanced Therapies

Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics

Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd

Sheela Upadhyaya | Life Science Advisor in Rare Diseases & Special Advisor | Openflex Ltd » speaking at Advanced Therapies

Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd

Renaud Vaillant, CEO, Alaya.bio

Renaud Vaillant | CEO | Alaya.bio » speaking at Advanced Therapies

Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics

Giuliana Vallanti, Vice President of Development and R&D for Cell & Gene Therapy, AGC Biologics

Giuliana Vallanti | Vice President of Development and R&D for Cell & Gene Therapy | AGC Biologics » speaking at Advanced Therapies

Jan Van Hauwermeiren, VP Business Development, Trince

Jan Van Hauwermeiren | VP Business Development | Trince » speaking at Advanced Therapies

David Venables, Chief Executive Officer, Laverock Therapeutics

Joshi Venugopal, General Manager and Head of Europe, Novartis Gene Therapies

Valentin von Werz, PhD Student, TU Wien

Valentin von Werz | PhD Student | TU Wien » speaking at Advanced Therapies

Alain Wagner, Director of Research, CNRS

Qizhao Wang, CTO, AAVnerGene

Ruizhi Wang, Chief Executive Officer/Founder, Abselion

Emily Warner, Principal Scientist, Ikarovec Limited

Ben Weil, Director of Manufacturing, INmune Bio

Adrian Westhaus, Postdoctoral Researcher, Genethon

Caroline Weydert, Regional Specialist Genomics (Biopharma), Bio-Rad

Caroline Weydert | Regional Specialist Genomics (Biopharma) | Bio-Rad » speaking at Advanced Therapies

Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading

Chris Williams, Chief Business Officer, Autolus Therapeutics

Chris Williams | Chief Business Officer | Autolus Therapeutics » speaking at Advanced Therapies

Kate Witkowska, Strategic Partnerships Director, Genomics England

Kate Witkowska | Strategic Partnerships Director | Genomics England » speaking at Advanced Therapies

Tim Witney, Professor of Molecular Imaging, Kings College London

Craig Woods, 07561524791, Forge Genetics

Su Xiao, Chief Technical Operations Officer, Neurophth Therapeutics

Shao-An Xue, Professor, Zhengzhou University of Technology

Ilya Yasny, Partner, LanceBio Ventures

Ilya Yasny | Partner | LanceBio Ventures » speaking at Advanced Therapies

Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies

Mana Yen | Global Executive Director - Health systems | Novartis Gene Therapies » speaking at Advanced Therapies

Andrea Zobel, Senior Director, Personalized Supply Chain, World Courier


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150